4-methoxyamphetamine has been researched along with everolimus in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 7 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Fahy, M; Kedhi, E; Kereiakes, DJ; Parise, H; Serruys, PW; Smits, PC; Stone, GW | 1 |
| Bøtker, HE; Christiansen, EH; Hansen, HS; Hansen, KN; Jensen, LO; Kaltoft, A; Krusell, LR; Lassen, JF; Madsen, M; Maeng, M; Ravkilde, J; Thayssen, P; Thuesen, L; Tilsted, HH | 1 |
| Antoniucci, D; Carrabba, N; Dovellini, EV; Migliorini, A; Parodi, G; Valenti, R; Vergara, R | 1 |
| Ahn, HS; Chae, IH; Kandzari, DE; Kang, HJ; Kang, J; Kang, SH; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, KW; Park, YB; Youn, TJ | 1 |
| Bae, JH; Cho, Y; Choi, SH; Gwon, HC; Hahn, JY; Jang, Y; Jeong, MH; Kim, HS; Koo, BK; Lee, JH; Park, JS; Rha, SW; Song, YB; Yoon, JH; Yu, CW | 1 |
| Dias, S; Petrou, P | 1 |
| Airaksinen, JKE; de Belder, A; de Bruyne, B; Karjalainen, PP; Kervinen, K; Lalmand, J; Nammas, W; Rivero-Crespo, F; Ylitalo, A | 1 |
| Airaksinen, J; Berland, J; Carrié, D; Christen, T; Dawkins, KD; Elhadad, S; Erglis, A; Janssens, L; Jobe, RL; Kereiakes, DJ; Masotti, M; Mehta, SR; Meredith, IT; Moreno, R; Reitman, A; Stein, B; Windecker, S | 1 |
| Horinaka, S; Ishimitsu, T; Yano, H | 1 |
| Chang, CJ; Chou, SH; Hsiao, FC; Hsu, LA; Lee, HF; Lin, CP; Lin, YC; Tsai, CT; Tung, YC; Yu, FC | 1 |
| Briguori, C; Condorelli, G; Conrotto, F; De Luca, L; De Marco, A; Esposito, G; Ferrante, G; Franzone, A; Indolfi, C; Lucisano, L; Musto, C; Pacchioni, A; Paradies, V; Piccolo, R; Pivato, CA; Presbitero, P; Reimers, B; Sardella, G; Stefanini, GG; Testa, L | 1 |
| Cequier, A; Choudhury, A; Colombo, A; de Winter, RJ; Gao, C; Garg, S; Hara, H; Hofma, SH; Kaul, U; Moreno, R; Ono, M; Onuma, Y; Petrov, I; Serruys, PW; Smits, PC; Tonino, PAL; Zaman, A | 1 |
| Arroyo, D; Benamer, H; Champagne, S; Chevalier, B; Garot, P; Gautier, A; Hovasse, T; Lefèvre, T; Neylon, A; Sanguineti, F; Unterseeh, T | 1 |
| Al-Shaibani, S; Arevalos, V; Bastos-Fernandez, G; Biscaglia, S; Bordes, P; Brugaletta, S; Campo, G; Diletti, R; Escaned, J; Flores, X; Gabani, R; Gomez-Hospital, JA; Gomez-Lara, J; Gonzalo, N; Grima Sopesens, N; Ielasi, A; Iñiguez, A; Jimenez, M; Jimenez-Diaz, V; Jiménez-Quevedo, P; Lenzen, M; Maristany, J; Ortega-Paz, L; Oyarzabal, L; Pineda, J; Rodes-Cabau, J; Romaguera, R; Sabaté, M; Serra, A; Serruys, PW; Silvestro, A; Spione, F; Tebaldi, M; Tespili, M | 1 |
| Bennett, J; Cutlip, DE; Doros, G; Garcia-Garcia, HM; Gharib, EG; Kandzari, DE; Koolen, JJ; Roguin, A; Waksman, R | 1 |
| Airaksinen, JKE; Bouisset, F; Collet, C; De Bruyne, B; Frambach, P; Karjalainen, PP; Kervinen, K; Lalmand, J; Mizukami, T; Pijls, NHJ; Romppanen, H; Roza da Costa, B; Sia, J; Tonino, PAL; Van der Heyden, J | 1 |
1 review(s) available for 4-methoxyamphetamine and everolimus
| Article | Year |
|---|---|
A mixed treatment comparison for short- and long-term outcomes of bare-metal and drug-eluting coronary stents.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Death; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2016 |
8 trial(s) available for 4-methoxyamphetamine and everolimus
| Article | Year |
|---|---|
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Death; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Proportional Hazards Models; Prospective Studies; Single-Blind Method; Sirolimus | 2011 |
2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Death; Denmark; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Single-Blind Method; Sirolimus; Thrombosis; Treatment Outcome | 2012 |
Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting Stents.
Topics: Aged; Death; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Retrospective Studies; Sirolimus | 2013 |
Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial.
Topics: Acute Coronary Syndrome; Aged; Death; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Single-Blind Method; Time Factors; Titanium; Treatment Outcome | 2016 |
Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Death; Diabetes Complications; Diabetes Mellitus; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Polymers; Sirolimus; Treatment Outcome | 2017 |
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
Topics: Death; Drug-Eluting Stents; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Sirolimus; Stents; Thrombosis; Treatment Outcome | 2022 |
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes.
Topics: Absorbable Implants; Cardiovascular Agents; Coronary Artery Disease; Death; Drug-Eluting Stents; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Prosthesis Design; Sirolimus; Treatment Outcome | 2022 |
Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Death; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Stents; Treatment Outcome | 2023 |
7 other study(ies) available for 4-methoxyamphetamine and everolimus
| Article | Year |
|---|---|
Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Postoperative Complications; Registries; Sirolimus; Treatment Outcome | 2012 |
Comparison of the first- and second-generation limus-eluting stents for bifurcation lesions from a Korean multicenter registry.
Topics: Aged; Animals; Coronary Artery Disease; Death; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Republic of Korea; Retrospective Studies | 2015 |
Impact of everolimus-eluting stent length on long-term clinical outcomes of percutaneous coronary intervention.
Topics: Aged; Angiography; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Death; Diabetes Complications; Diabetes Mellitus; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Retrospective Studies; Stents; Thrombosis; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2018 |
Procedural and One-Year Clinical Outcomes of Long 48 mm Xience Xpedition Everolimus-Eluting Stent in Complex Long Diffuse Coronary Artery Lesions.
Topics: Coronary Artery Disease; Coronary Vessels; Death; Drug-Eluting Stents; Everolimus; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Percutaneous Coronary Intervention; Prosthesis Design; Retrospective Studies; Sirolimus; Stents; Treatment Outcome | 2022 |
One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Anticoagulants; Death; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Thrombosis; Treatment Outcome | 2022 |
Safety and efficacy of 48 mm Xience Xpedition everolimus-eluting stent for the treatment of long coronary lesions.
Topics: Cardiovascular Agents; Death; Drug-Eluting Stents; Everolimus; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Percutaneous Coronary Intervention; Prosthesis Design; Risk Factors; Sirolimus; Time Factors; Treatment Outcome | 2022 |
Sex Differences in 10-Year Outcomes Following STEMI: A Subanalysis From the EXAMINATION-EXTEND Trial.
Topics: Death; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Sex Characteristics; Sirolimus; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |